Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Beverly Hospital, Beverly, Massachusetts
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Register for Updates
A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
NCT07016750
Recruiting
KB803-EYE-01 is a Phase 3 double-blind, intra-patient crossover study, to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/01/2025
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Register for Updates
Noninvasive Continuous BP Monitoring in Newborns Based on Pulsatile Signal Morphological Features Using NIRS
NCT06994494
Recruiting
The goal of this study is to evaluate if a novel near-infrared spectroscopy (NIRS) device can accurately estimate blood pressure in newborns at risk for unstable blood pressure. The main questions it aims to answer are: * Can NIRS accurately estimate blood pressure when compared to the gold standard, arterial line blood pressure * Can NIRS accurately estimate blood pressure when compared to infants with cuff blood pressure monitoring Researchers will compare NIRS-based estimates to arterial li... Read More
Gender:
ALL
Ages:
Between 24 weeks and 44 weeks
Trial Updated:
07/01/2025
Locations: Massachusettes General Hospital, Boston, Massachusetts
Conditions: Unstable Blood Pressure, Hypotension
Register for Updates
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
NCT06872684
Recruiting
The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/01/2025
Locations: Lahey Hospital and Medical Center, Burlington, Massachusetts
Conditions: Aneurysm, Aneurysm, Intracranial
Register for Updates
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Metastatic Colorectal Cancer
Register for Updates
Sleep Treatment Education Program for Cancer Survivors: STEP-Together
NCT06736548
Recruiting
This single-arm research study of off-treatment cancer survivors with self-reported symptoms of insomnia will test the Sleep Treatment Education Program Together (STEP-Together) intervention which is delivered as a synchronous group session by videoconference.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/01/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Insomnia, Insomnia Chronic, Survivorship
Register for Updates
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT06321484
Recruiting
The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/01/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
NCT05773144
Recruiting
To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Colonic Neoplasms
Register for Updates
Metastatic Leiomyosarcoma Biomarker Protocol
NCT05653388
Recruiting
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: Dana- Farber, Boston, Massachusetts
Conditions: Leiomyosarcoma
Register for Updates
Hydrogen's Feasibility and Safety as a Therapy in ECPR
NCT05574296
Recruiting
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Cardiac Arrest, Extracorporeal Membrane Oxygenation, Reperfusion Injury
Register for Updates
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
NCT04928677
Recruiting
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/01/2025
Locations: Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts
Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Register for Updates